Thrombophilia can be defined as a predisposition to thrombosis. Abnormalities in haemostasis that are associated with clinical thrombophilia include heritable defects, such as mutations in the genes encoding the natural anticoagulants antithrombin, protein C and protein S, or clotting factors prothrombin and factor V, and adquired factors defects, such as antiphospholipids.1,2,3,4 The most common acquired thrombophilia’s are antiphospholipids, which comprise lupus inhibitors and anticardiolipin antibodies.5,6,7,8 Women with thrombophilic defects have been shown to be at increased risk, not only of pregnancy associated thromboembolism, but also...

During the period from June 2012 to August 2013, a prospective observational case-control study was carried out in the Section of Gynecology and Obstetrics of a private medical clinic in cooperation with the University State of São Paulo (USP), Brazil. Institutional review board approval was obtained for this study. Data were collected at entry to the study, by personal interview. Sonographic images of the obstetrical exams of patients in this study were obtained from B-mode and color Doppler amplitude. Two groups of women were enrolled....

Our statistical analysis showed a slightly increased association, which was not significant between Factor V Leiden, RPL and thrombotic placental damage. Analysis RPL subgroups revealed an association between FVL and first trimester loss. Due to the limitations of the available data, the analysis on factor V Leiden incorporates both homozygous and heterozygous carriers. These women were found to be at higher risk of pregnancy loss in the second compared with the first trimester (OR 5.0; 95% CI 2.2-8.9 and 2.0; 95% CI 1.02-03.80, respectively). 11,12,13...

CONCLUSION The management of thrombophilia during pregnancy encompasses primary thromboprophylaxis in asymptomatic women, secondary prophylaxis of recurrences in women who have previously developed thrombosis, and the treatment of acute thrombotic episodes. This study observed strong association of thrombophilia with thrombotic placental damage and adverse perinatal outcomes. Our findings have important implications for therapy and provide a rationale for clinical trials of thromboprophylaxis for affected women followed by serial placental gray-scale ultrasound and resistance blood flow Doppler. The diagnosis has serious implications not only for the...

MRM MACHADO,Department of Radiology, University of São Paulo,[email protected]; MC CHAMMAS, doctor of Hospital das Clínicas da Faculdade de Medicina da Universidade of São Paulo (USP), Medical director of Service of Ultrasound (USP).

1. Walker ID. Thrombophilia in pregnancy. J Clin Pathol 2000; 53: 573-580.Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol 2003; 1:1-28. 2. HatzisT, Cardamakis E, Drivalas E, Makatsoris K, Bevan D, Pantos C. Increased resistance to activated protein C and Factor V Leiden in recurrent abortions. Review of other hypercoagulability factors. Europ J of Contracep and Reprod Health Care 1999; 4: 135-144. 3. Higashino M, Takakuwa K, Arakawa M, Tamura M, Yasuda M, Tanaka K. Anti-cardiolipin antibody and anti-cardiolipin beta-2-glycoprotein I antibody in patients with...